Inequality in the availability of expensive treatments

Journal of the Royal College of Physicians of London

Volumn 33, Issue 5, 1999, Pages 448-449

  Thompson, Alan J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON;

DRUG COST; HEALTH CARE ACCESS; MULTIPLE SCLEROSIS; SHORT SURVEY;

COST-BENEFIT ANALYSIS; GREAT BRITAIN; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PRACTICE GUIDELINES;

EID: 0032749808     PISSN: 00358819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (16)

1. McDonald WI. New treatments for multiple sclerosis (editorial). Br Med J 1995;310:345-6.
2. Andersen O, Runmarker B. What proportion of the total MS population comply with activity criteria actually utilised as indications for beta-interferon therapy? J Neurol 1997;244(Suppl 3):S66.
3. Mumford CJ. Beta Interferon and multiple sclerosis: why the fuss? Q J Med 1996;89:1-3.
4. Anon. Interferon beta 1B - hope or hype? Drug Therapeut Bull 1996; 34:9-11.
5. McDonald WI for the Association of British Neurologists UK. New treatments for multiple sclerosis. London: Association of British Neurologists, 1994.
6. Winyard G. NHS Executive issued advice to help NHS plan for introduction of the treatment. Br Med J 1997;314:601-2.
7. Richards RG. Interferon beta in multiple sclerosis: clinical cost effectiveness falls at the first hurdle. Br Med J 1996;313:1159.
8. Parkin D, McNamee P, Jacoby A, Miller P, et al. A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assess 1998; 2:1-58.
9. Holmes J. Avoidance of the need for social care should also be taken into account. Br Med J 1997;314:601.
10. Carton H, Loos R, Pacolet J, Versieck K, Vlietinck R. Utilisation and cost of the professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium). J Neurol Neurosurg Psychiatry 1998;64:444-50.
11. Walley T, Barton S. A purchaser perspective of managing new drugs: interferon beta as a case study. Br Med J 1995;311:796-9.
12. Young C. Improving health care for multiple sclerosis patients - a clinical neurology based service. Measured steps. Meeting of the MS Society, 1998.
13. Zajicek J. Personal communication.
14. Walley T, Edwards RT. Is there a need for an independent centre for pharmaco-economics in the UK? Pharmacoeconomics 1994;5:93-100.
15. Rawlins M. In pursuit of quality: the National Institute for Clinical Excellence. Lancet 1999;353:1079-80.
16. Horton R. NICE: a step forward in the quality of NHS care. Lancet 1999;353:1028-9.